

Synthesis of 3'-1,2,4-Triazolo- and 3'-1,3,4-Thiadiazoliminothymidines

Yaseen A. Al-Soud¹ and Najim A. Al-Masoudi²

¹Department of Chemistry, College of Science, University of Al al-Bayt, al-Mafraq, Jordan

²Fakultät für Chemie, Universität Konstanz, Postfach 5560, D-78457 Konstanz, Germany


Received 31 October 2002; revised 18 November 2003

ABSTRACT: New 5'-acetyl-3'-1,3,4-thiadiazoliminothymidines **11**, **14** were prepared, via spontaneous rearrangements, by cycloaddition of 5'-acetyl-3'-deoxy-3'-isothiocyanothymidine **9** with 1-aza-2-azoniaallene hexachloantimonates. Similarly, 3'-cyano analogue **19** was reacted with the same cumulenes to furnish 3'-1,2,4-triazolo-thymidines **22**, **24**, and **26**. Deblocking of the acylated products afforded the free nucleosides. © 2003 Wiley Periodicals, Inc. *Heteroatom Chem* 14:298–303, 2003; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hc.10146

INTRODUCTION

Intensive efforts are underway worldwide to develop chemotherapeutic agents effective against AIDS, since the attempts are continued to discover drugs which can interfere with a stage in the viral replicative cycle without damaging the normal processes of the host cell. Several 3'-modified 2',3'-dideoxynucleosides (AZT **1**, CNT **2**, ddi, ddC, ddT) [1–5] are approved as anti-AIDS drugs targeted as effective inhibitors of HIV reverse transcriptase (RT), the enzyme which catalyzes phosphodiester bond formation on route to the synthesis of a DNA copy of the viral RNA [6]. However, these compounds are quite toxic and not free of undesirable side effects [7] and for this reason different

laboratories continue to search for new 3'-modified 2',3'-dideoxynucleosides exhibiting anti-AIDS activity. The most promising agents of this class of drugs are 3'-deoxy DNA nucleosides and 3'-azole derivatives [8–12], which might fulfill the need of this strategy. Herdewijin et al. [13] and Hirota et al. [14] have reported the synthesis of compounds, in which the azide group of AZT is transformed to a triazole ring **3**, but these compounds did not show appreciable activity against HIV. Our work here is concerned with the synthesis of new 3'-azole analogues from the cycloaddition of 5'-acetyl-3'-deoxy-3'-isothiocyanothymidine **9** and 3'-cyano-analogue **19**, prepared from the antiviral nucleoside CNT [4,5], with some reactive cumulenes. In our recent work, these cumulenes have been used in the synthesis of new types of 1,2,4-triazole compounds such as C-ribonucleosides [15,16], acyclic C-nucleosides and homo-C-analogues [17], (D-manno-pentitol-1-yl)-analogues [18], as well as those 1,2,4-triazoles attached to thymine [19], phthalimide [20], indole [21], quinolone [21], and benzotriazole [22].




Correspondence to: N. A. Al-Masoudi; e-mail: Najim. Al-Masoudi@uni-konstanz.de.
© 2003 Wiley Periodicals, Inc.

RESULTS AND DISCUSSION

3'-Isothiocyanatothymidine **8** was prepared according to the methods of Monila et al. [23] and Cech et al. [24], starting from the 3'-azido-3'-deoxythymidine **1** via two steps. Acetylation of **8** with acetic anhydride in dry pyridine afforded 5'-acetate **9** as a colorless foam in 73% yield. The α,α -dichloroazo compound **4a** [25] was obtained by chlorination of the bis-hydrazone, and the 1-aza-2-azoniaallene salt **5a** [26,27] by the treatment of **4a** at -60°C with SbCl_5 . Addition of **9** to the reactive intermediate **5a**, by employing the methods of Jochims et al. [15,28], lead to a color change of the orange suspension of **5a** between -60°C and $+23^\circ\text{C}$ indicating a cycloaddition reaction. The resulting 1,3,4-thiadiazolium hexachloroantimonate **10a** lost its CMe_2Cl group and

furnished the protonated salt **10b**. Deprotonation gave 1,3,4-thiadiazole **11** in 55% yield. Deblocking of **11** with NaOMe in MeOH at 23°C afforded the free nucleoside **12** in 75% yield. The concerted cycloadditions to isothiocyanates are known to occur both on the $\text{C}=\text{S}$ and the $\text{C}=\text{N}$ bond in a competitive manner [29]. The isothiocyanate group of compound **9** reacts as *S*-nucleophile resulting in 2,5-dihydro-1,3,4-thiadiazole **11** (cf. **16** [25]) and not as *N*-nucleophile, which would have resulted in an isomeric 4,5-dihydro-1*H*-1,3,4-triazole-5-thione (cf. **17** [28]) (Scheme 1). Compounds **11** and **12** were identified from the ^1H NMR and ^{13}C NMR spectra, which are in agreement with those of thiadiazole analogues obtained by Jochims et al. [15,28]. The ^1H NMR spectrum of **11** is characterized by the presence of two




SCHEME 1 Reagents and conditions: (i) SbCl_5 ; CH_2Cl_2 , -60°C to 23°C , 7 h, CH_2Cl_2 , 23°C ; (ii) aq. NaHCO_3 , 2 h, 23°C ; (iii) NaOMe , MeOH , 10 h, 23°C .

singlets at δ_{H} 1.91 and 1.88, which were attributed to the two 2''-methyl groups. The ^{13}C NMR shifts 106.7 and 177.5 (DMSO- d_6) observed for **12** are assigned to C-2'' and C-5'' of the thiadiazole ring, and δ_{C} 28.2 and 28.0 attributed to the methyl on C-2''.

Analogously, the heteroallene **7** carrying a *tert*-butyl group were used to synthesize neutral 2-substituted 1,2,4-triazoles [30,31]. Compounds **7**, which formed at low temperature from **6** [15,18] and SbCl_5 , reacted with the isothiocyanate **9** via C=S cycloaddition to give the nitrilium ion **13a** as an intermediate. The latter is cyclized to the thiadiazolium salt **13b** affording, after the loss of the *tert*-butyl group (as isobutene [18]), the unseparable iminium salt **13c**. The *tert*-butyl group was probably lost during and not after the rearrangement. In situ deprotonation of **13c** with saturated aqueous solution of NaHCO_3 afforded the thiadiazole **14**. Removal of the acetate group at C-5' by NaOMe in MeOH gave **15** in 79% yield (Scheme 1). The structure of **14** was identified from the ^1H NMR and mass spectra. The H-1' appeared as a doublet of doublets at δ_{H} 6.34 ($J_{1',2'a} = 6.0$ Hz, $J_{1',2'b} = 4.1$ Hz), whereas the multiplets at δ_{H} 2.68, 3.79, 4.19, and 4.55 were attributed to H-2'a,b, H-5'a,b, respectively. The aromatic protons appeared at δ_{H} 7.90 and 7.88 as from an AB system. The structure of **15** was proven by homo- and heteronuclear NMR spectroscopy methods and by mass spectra. The $^3J_{\text{C,H}}$ correlation in the HMQC [32] spectrum of C-5'' at δ_{C} 156.2 and H-3' at δ_{H} 4.50 is an additional proof for the C=S cycloaddition. Furthermore,

L'abbé et al. reported values in the range of δ_{C} 151–164 ppm for C-2 and of δ_{C} 149–155 ppm for C-5 for several thiadiazoles of type **18** [18,33], which are in agreement with the data shown by compound **15** (δ_{C} 147.7 for C-2'' and δ_{C} 156.2 for C-5'').

Our attempt to modify the 3'-position of the thymidine by introducing a disubstituted 1,2,4-triazole via cycloaddition reaction of the reactive 1-aza-2-azoniaallene salts **5a–c** with the sugar nitrile **19** was successful. In a similar manner as for the preparation of **5a**, the intermediates **5b,c** were prepared from the α,α -dichloroazo compounds **4b,c** by treatment with SbCl_5 at -60°C . At approximately -30°C the color changed from orange to brown, indicating that **5a–c** underwent cycloaddition reactions with the sugar nitrile **19** to give the unseparable 3'-(3*H*-1,2,4-triazolium-5-yl)thymidine hexachloroantimonates **20a–c**. After the increase of the temperature above -30°C , **20a–c** rearranged spontaneously by migration of the alkyl group at C-3'', via [1,2-shift] [30,34] to N-2'' accompanied by the elimination of the CClR^1R^2 group at N-1'', leading to the protonated 1,2,4-triazolium salts **21a–c**. In situ deprotonation with aqueous NaHCO_3 [30,31] afforded, after chromatographic purification, the 3'-(1,5-disubstituted-1,2,4-triazole) analogues **22**, **24**, and **26**, as foam, in 72, 75, and 78% yield, respectively. Treatment of **22**, **24**, and **26** with NaOMe in MeOH afforded the free nucleosides **23**, **25**, and **27** respectively in 86, 81, and 78% yield (Scheme 2). The structures of **22–27** were identified by their ^1H NMR, ^{13}C NMR, and mass



SCHEME 2 Reagents and conditions: (i) SbCl_5 ; CH_2Cl_2 , -60°C to 23°C , 7 h, CH_2Cl_2 , 23°C ; (ii) aq. NaHCO_3 , 2 h, 23°C ; (iii) NaOMe , MeOH, 10 h, 23°C .

spectra. The ^1H NMR spectra of **22–25** showed similar patterns. H-1' appeared as triplet or doublet of doublets at δ_{H} 6.21, 6.31, 6.23, and 6.32, respectively. The singlets at δ_{H} 2.38, 2.35, 2.34, and 2.33 were attributed to the methyl groups at C-5'' of the triazole ring. The methyl and ethyl groups at N-1'' were identified. Compound **27** was selected for homo- and heteronuclear NMR study. Gradient selected HMBC [35] spectrum allowed via $^2J_{\text{C,H}}$ and $^3J_{\text{C,H}}$ couplings the assignment of most of the carbon atoms. C-2'' at δ_{C} 159.9 was identified from its $^2J_{\text{C,H}}$ correlation to H-3' at δ_{H} 3.52. CH_2 -9'' at δ_{C} 49.7 was identified from its $^2J_{\text{C,H}}$ correlation to C-10'' at δ_{C} 156.5, since CH_2 -5'' at δ_{H} 1.55 was identified from its $^3J_{\text{C,H}}$ correlation to C-10'' as well. The rest azepine and sugar protons were fully analyzed using the same method.

EXPERIMENTAL

General Procedure [15–22] for the Preparation of the Acylated 3'-(Disubstituted 1,2,4-triazolo)- and 3'-(Disubstituted-1,3,4-thiadiazolimino)-2',3'-dideoxythymidines **11**, **14**, **22**, **24**, and **26**

A solution of SbCl_5 (0.90 g, 3.0 mmol) in CH_2Cl_2 (10 ml) was added dropwise to a stirred, cooled (-60°C) solution of compound **9** (0.27 g, 1.0 mmol) or **19** (0.29 g, 1.0 mmol) and **4a–c** or **6** (3.0 mmol) in CH_2Cl_2 (15 ml). After stirring the mixture at -60°C for 1 h, then at 0°C for 1 h, and finally at 23°C for 10 min, the solvent was evaporated to dryness. The brown residue was dissolved in MeCN (15 ml). After cooling the mixture to 0°C , an aqueous solution of NaHCO_3 [2.52 g (30 mmol) in H_2O (10 ml)] was added slowly. The mixture was stirred at 23°C for 30 min and filtered. The organic solvent was removed in vacuo, and the aqueous phase was extracted with CHCl_3 (3×20 ml). The combined organic extracts were washed with water (3×10 ml), dried (Na_2SO_4), filtered, and evaporated to dryness. The amorphous residue was purified on a column of SiO_2 (15 g) using first CHCl_3 and then CHCl_3 –MeOH (99:1) as eluents.

5'-Acetyl-2',3'-dideoxy-3'-(2,3-dihydro-5,5-dimethyl-[1,3,4]thiadiazolimino)thymidine (11). From **4a** (0.55 g). Yield: 0.23 g (58%). ^1H NMR (CDCl_3): δ 11.28 (br s, 1H, NH); 7.68 (d, 1H, $J_{6,\text{Me}} = 1.0$ Hz, H-6); 6.55 (t, 1H, $J_{1',2'a} = J_{1',2'b} = 6.3$ Hz, H-1'); 5.15 (m, 1H, H-3'); 4.48 (m, 1H, H-4'); 4.12 (d, 2H, H-5'a, H-5'b); 2.71 (m, 2H, H-2'a, H-2'b); 2.08 (s, 3H, OAc); 1.91, 1.88 (2s, 6H, $2 \times \text{C}_{5''}\text{-Me}$); 1.85 (d, 3H, $J = 1.0$ Hz, $\text{C}_5\text{-Me}$). Anal. calc. for $\text{C}_{16}\text{H}_{21}\text{N}_5\text{O}_5\text{S}$ (395.44): C, 48.60; H, 5.35; N, 17.71. Found: C, 48.41; H, 5.34; N, 17.39. MS: m/z (FAB) 396 (MH^+).

5'-Acetyl-2',3'-dideoxy-3'-(2,3-dihydro-5-methyl-3-(2,4,6-trichlorophenyl)-[1,3,4]thia-diazolimino)thymidine (14). From **6** (0.98 g). Yield: 0.36 g (64%). ^1H NMR (CDCl_3): δ 11.29 (br s, 1H, NH); 7.90, 7.88 (AB, 2H, $J_{\text{AB}} = 2.5$ Hz, ArH); 7.72 (d, 1H, $J_{6,\text{Me}} = 1.0$ Hz, H-6); 6.34 (dd, 1H, $J_{1',2'a} = 6.0$ Hz, $J_{1',2'b} = 4.1$ Hz, H-1'); 4.55 (m, 1H, H-3'); 4.19 (m, 1H, H-4'); 3.79 (m, 2H, H-5'a, H-5'b); 2.68 (m, 2H, H-2'a, H-2'b); 2.11 (s, 3H, OAc); 1.91 (s, 3H, $\text{C}_{2''}\text{-Me}$); 1.86 (d, 3H, $J = 1.0$ Hz, $\text{C}_5\text{-Me}$). Anal. calc. for $\text{C}_{21}\text{H}_{19}\text{Cl}_3\text{N}_5\text{O}_5\text{S}$ (559.83): C, 45.05; H, 3.42; N, 12.51. Found: C, 44.83; H, 3.40; N, 12.27. MS: m/z (FAB) 560/562 (MH^+).

5'-Acetyl-2',3'-dideoxy-3'-(1,5-dimethyl-1H-[1,2,4]triazol-3-yl)thymidine (22). From **4a** (0.55 g). Yield: 0.26 g (72%). ^1H NMR (CDCl_3): ^1H NMR (600 MHz, $\text{DMSO}-d_6$): δ 7.75 (d, 1H, $J_{6,\text{Me}} = 1.2$ Hz, H-6); 6.21 (t, 1H, $J_{1',2'a} = J_{1',2'b} = 6.0$ Hz, H-1'); 4.10 (m, 1H, H-4'); 3.64 (s, 3H, $\text{N}^{2''}\text{-Me}$); 3.61 (dd, 1H, $J_{4',5'a} = 5.5$ Hz, $J_{5'a,5'b} = 11.0$ Hz, H-5'a); 3.52 (dd, 1H, $J_{4',5'b} = 3.5$, 11.0 Hz, H-5'b); 3.50 (m, 1H, H-3'); 2.63 (m, 1H, H-2'a); 2.48 (m, 1H, H-2'b); 2.38 (s, 3H, $\text{C}_{5''}\text{-Me}$); 1.85 (d, 3H, $J = 1.2$ Hz, $\text{C}_5\text{-Me}$). Anal. calc. for $\text{C}_{16}\text{H}_{21}\text{N}_5\text{O}_5$ (363.37): C, 52.89; H, 5.82; N, 19.27. Found: C, 52.62; H, 5.68; N, 19.01. MS: m/z (FAB) 364 (MH^+).

5'-Acetyl-2',3'-dideoxy-3'-(1-Ethyl-5-methyl-1H-[1,2,4]triazol-3-yl)thymidine (24). From **4b** (0.63 g). Yield: 0.28 g (75%), foam. ^1H NMR (CDCl_3): 11.37 (br s, 1H, NH); 7.72 (d, 1H, $J_{6,\text{Me}} = 1.0$ Hz, H-6); 6.23 (dd, 1H, $J_{1',2'a} = 6.5$ Hz, $J_{1',2'b} = 3.7$ Hz, H-1'); 4.13 (m, 1H, H-4'); 3.80 (q, 2H, $J = 7.0$ Hz, CH_2CH_3); 3.71 (s, 3H, $\text{N}^{2''}\text{-Me}$); 3.70 (dd, 1H, $J_{4',5'a} = 3.5$ Hz, $J_{5'a,5'b} = 11.5$ Hz, H-5'a); 3.60 (dd, 1H, $J_{4',5'b} = 3.0$ Hz, H-5'b); 3.56 (m, 1H, H-3'); 2.65 (m, 1H, H-2'a); 2.46 (m, 1H, H-2'b); 2.34 (s, 3H, $\text{C}_{5''}\text{-Me}$); 2.10 (s, 3H, OAc); 1.86 (d, 3H, $J = 1.0$ Hz, $\text{C}_5\text{-Me}$); 1.08 (t, 3H, CH_2CH_3). Anal. calc. for $\text{C}_{17}\text{H}_{23}\text{N}_5\text{O}_5$ (377.40): C, 54.10; H, 6.11; N, 18.56. Found: C, 53.86; H, 6.00; N, 18.32. MS: m/z (FAB) 378 (MH^+).

5'-Acetyl-2',3'-dideoxy-3'-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[1,5-a]azepin-2-yl)-thymidine (26). From **4c** (0.71 g). Yield: 0.29 g (78%). ^1H NMR (600 MHz, CDCl_3): δ 11.22 (br s, 1H, NH); 7.70 (d, 1H, $J_{6,\text{Me}} = 1.0$ Hz, H-6); 6.24 (dd, 1H, $J_{1',2'a} = 7.3$ Hz, $J_{1',2'b} = 4.0$ Hz, H-1'); 4.18 (ddd, 1H, $J_{4',5'b} = 3.2$ Hz, H-4'); 4.00 (m, 2H, CH_2 -5''); 3.81 (m, 1H, H-3'); 3.77 (dd, 1H, $J_{4',5'a} = 5.2$ Hz, $J_{5'a,5'b} = 11.0$ Hz, H-5'a); 3.71 (dd, 1H, $J_{4',5'b} = 3.0$ Hz, H-5'b); 2.75 (m, 1H, H-2'a); 2.72 (m, 2H, CH_2 -6''); 2.54 (m, 1H, H-2'b); 2.13 (s, 3H, OAc); 1.77 (m, 2H, CH_2 -8''); 1.81 (d, 3H, $J = 1.0$ Hz, $\text{C}_5\text{-Me}$); 1.59 (m, 2H, CH_2 -9''); 1.48 (m, 2H, CH_2 -7''). Anal. calc. for $\text{C}_{17}\text{H}_{23}\text{N}_5\text{O}_5$ (377.4): C,

54.10; H, 6.11; N, 18.56. Found: C, 53.86; H, 6.00; N, 18.32. MS: m/z (FAB) 378 (MH⁺).

General Procedure for Preparation of the Free Nucleosides **12**, **15**, **23**, **25**, and **27**

A solution of the acylated nucleosides (0.75 mmol) in dry MeOH (10 ml) was stirred in 0.3 M NaOMe (7 ml) at 23°C for 7 h. The solution was neutralized with 0.1 M HCl and filtered. The filtrate was evaporated to dryness and the residue was poured onto a column of SiO₂ (10 g). Elution with MeOH, in gradient, (0–10%) and CHCl₃ afforded the pure nucleoside.

2',3'-Dideoxy-3'-(2,5-dihydro-5,5-dimethyl-[1,3,4]-thiadiazolimino)thymidine (12). From **11** (0.30 g) Yield: 0.20 g (75%), as foam. ¹H NMR (600 MHz, DMSO-*d*₆): δ 11.30 (br s, 1H, NH); 7.73 (d, 1H, $J_{6,Me} = 1.0$ Hz, H-6); 6.45 (t, 1H, $J_{1',2'a} = J_{1',2'b} = 6.5$ Hz, H-1'); 5.22 (t, 1H, $J_{5'a,5'b,OH} = 5.0$ Hz, C_{5'}-OH); 4.89 (m, 1H, H-3'); 4.15 (m, 1H, H-4'), 3.63 (br s, 2H, H-5'a, H-5'b); 2.65–2.59 (m, 2H, H-2'a, H-2'b); 1.87, 1.86 (2s, 6H, 2 × Me); 1.80 (d, 3H, $J = 1.0$ Hz, C₅-Me). ¹³C NMR (62.9 MHz, DMSO-*d*₆): δ 177.5 (C-5''); 163.5 (C-4); 150.1 (C-2); 136.5 (C-6); 109.6 (C-5); 106.7 (C-2''); 85.0 (C-4'); 84.2 (C-1'); 66.9 (C-3'); 61.0 (C-5'); 38.1 (C-2'); 28.2, 28.0 (C_{2''}-Me₂); 12.5 (C₅-Me). Anal. calc. for C₁₄H₁₉N₅O₄S (353.4): C, 47.58; H, 5.42; N, 19.82. Found: C, 47.35; H, 5.31; N, 19.59. MS: m/z (FAB) 354 (MH⁺).

2',3'-Dideoxy-3'-(2,3-dihydro-5-methyl-3-(2,4,6-trichlorophenyl)-[1,3,4]thiadiazolimino)-thymidine (15). From **14** (0.42 g). Yield: 0.29 g (79%), mp 201–204°C. ¹H NMR for (600 MHz, DMSO-*d*₆): δ 11.21 (br s, 1H, NH); 7.85 (s, 2H, ArH); 7.69 (d, 1H, $J_{6,Me} = 1.0$ Hz, H-6); 6.20 (dd, 1H, $J_{1',2'a} = 6.5$ Hz, $J_{1',2'b} = 4.2$ Hz, H-1'); 5.25 (t, 1H, $J_{5'a,5'b,OH} = 5.3$ Hz, C_{5'}-OH); 4.50 (m, 1H, H-3'); 4.15 (m, 1H, H-4'); 3.72–3.61 (m, 2H, H-5'a, H-5'b); 2.65–2.49 (m, 2H, H-2'a, H-2'b); 1.90 (C_{2''}-Me); 1.86 (d, 3H, $J = 1.0$ Hz, C₅-Me). ¹³C NMR (62.9 MHz, DMSO-*d*₆): 163.7 (C-4); 156.2 (C-5''); 150.3 (C-2); 147.7 (C-2''); 135.7, 135.6, 133.4, 128.7, 128.6, 128.4 (Aryl); 136.5 (C-6); 109.6 (C-5); 85.1 (C-4'); 84.5 (C-1'); 68.1 (C-3'), 61.5 (C-5'); 37.5 (C-2'); 17.3 (C_{2''}-Me); 12.6 (C₅-Me). Anal. calc. for C₁₉H₁₇Cl₃N₅O₄S (517.8): C, 44.07; H, 3.31; N, 13.53. Found: C, 43.85; H, 3.20; N, 13.21. MS: m/z (FAB) 540/542 (MNa⁺).

2',3'-Dideoxy-3'-(1,5-dimethyl-1H-1,2,4-triazol-3-yl)thymidine (23). From **22** (0.27 g). Yield: 0.21 g (86%), as foam. ¹H NMR (600 MHz, DMSO-*d*₆): δ 11.40 (br s, 1H, NH); 7.78 (d, 1H, $J_{6,Me} = 1.1$

Hz, H-6); 6.15 (dd, 1H, $J_{1',2'a} = 7.5$ Hz, $J_{1',2'b} = 3.9$ Hz, H-1'); 5.30 (br s, 1H, C_{5'}-OH); 4.13 (dt, 1H, $J_{3',4'} = 8.8$ Hz, H-4'); 3.71 (s, 3H, N^{2''}-Me); 3.70 (dd, 1H, $J_{4',5'a} = 3.1$ Hz, H-5'a); 3.60 (dd, 1H, $J_{4',5'b} = 2.9$ Hz, H-5'b); 3.56 (m, 1H, H-3'); 2.65 (m, 1H, H-2'a); 2.46 (m, 1H, H-2'b); 2.35 (s, 3H, C_{5''}-Me); 1.86 (d, 3H, $J = 1.1$ Hz, C₅-Me). ¹³C NMR (62.9 MHz, DMSO-*d*₆): δ 163.9 (C-4); 161.0 (C-3''); 152.1 (C-5''); 150.0 (C-2); 137.1 (C-6); 110.2 (C-5); 87.1 (C-4'); 85.1 (C-1'); 61.7 (C-5'); 37.9 (C-2'); 34.5 (N^{2''}-Me); 29.1 (C-3'); 12.4 (C₅-Me); 11.30 (C_{2''}-Me). Anal. calc. for C₁₄H₁₉N₅O₄ (321.33): C, 52.33; H, 5.96; N, 21.79. Found: C, 52.01; H, 5.88; N, 21.58. MS: m/z (FAB) 344 (MNa⁺).

2',3'-Dideoxy-3'-(1-ethyl-5-methyl-1H-[1,2,4]triazol-3-yl)thymidine (25). From **24** (0.28 g). Yield: 0.20 g (81%), as foam. ¹H NMR (DMSO-*d*₆): δ 11.19 (br s, 1H, NH); 7.70 (d, 1H, $J_{6,Me} = 1.0$ Hz, H-6); 6.32 (dd, 1H, $J_{1',2'a} = 6.5$ Hz, $J_{1',2'b} = 3.6$ Hz, H-1'); 5.80 (t, 1H, $J_{5'a,5'b,OH} = 4.8$ Hz, C_{5'}-OH); 3.98 (m, 1H, H-4'); 3.78 (q, 2H, $J = 7.0$ Hz, CH₂CH₃); 3.75 (m, 1H, H-3'); 3.70 (s, 3H, N^{2''}-Me); 3.67 (m, 1H, H-5'a); 3.61 (m, 1H, H-5'b); 3.52 (m, 1H, H-3'); 2.60–2.51 (m, 2H, H-2'a, H-2'b); 2.33 (s, 3H, C_{5''}-Me); 1.86 (d, 3H, $J = 1.0$ Hz, C₅-Me); 1.11 (t, 3H, CH₂CH₃). ¹³C NMR (DMSO-*d*₆): 163.0 (C-4); 155.4 (C-3''); 150.1 (C-5''); 1484 (C-2); 136.7 (C-6); 109.6 (C-5); 87.0 (C-4'); 85.2 (C-1'); 61.5 (C-5'); 45.0 (CH₂CH₃); 37.4 (C-2'); 29.0 (C-3'); 13.1, 12.2, 10.2 (3 × Me). Anal. calc. for C₁₅H₂₁N₅O₄ (355.56): C, 53.72; H, 6.31; N, 20.88. Found: C, 53.51; H, 6.19; N, 20.53. MS: m/z (FAB) 378 (MNa⁺).

2',3'-Dideoxy-3'-(6,7,8,9-tetrahydro-5H-1,2,4-triazolo[1,5-a]azepin-2-yl)thymidine (27). From **26** (0.30 g). Yield: 0.21 g (78%), mp 129–132°C. ¹H NMR (600 MHz, DMSO-*d*₆): δ 11.20 (br s, 1H, NH); 7.71 (d, 1H, $J_{6,Me} = 1.0$ Hz, H-6); 6.19 (dd, 1H, $J_{1',2'} = 7.5$ Hz, $J_{1',2''} = 4.0$ Hz, H-1'); 5.30 (br t, 1H, C_{5'}-OH); 4.15 (m, 1H, H-4'); 3.92 (m, 2H, CH₂-9''); 3.72 (m, 1H, H-5'a); 3.69 (m, 1H, H-5'b); 3.52 (m, 1H, H-3'); 2.71 (m, 1H, H-2'a); 2.68 (m, 2H, CH₂-8''); 2.45 (m, 1H, H-2'b); 1.71 (m, 2H, CH₂-6''); 1.80 (d, 3H, $J = 1.0$ Hz, C₅-Me); 1.55 (m, 2H, CH₂-5''); 1.45 (m, 2H, CH₂-7''). ¹³C NMR (62.9 MHz, DMSO-*d*₆): δ 163.9 (C-4); 159.9 (C-2''); 156.5 (C-10''); 151.2 (C-2); 137.8 (C-6); 110.5 (C-5); 87.8 (C-4'); 85.0 (C-1'); 60.8 (C-5'); 49.7 (C-9''); 37.0 (C-2'); 29.3 (C-6''); 28.5 (C-3'); 27.8 (C-5''); 26.1 (C-8''); 24.4 (C-7''); 12.4 (C₅-Me). Anal. calc. for C₁₉H₂₅N₅O₄ (361.4): C, 56.40; H, 6.41; N, 19.38. Found: C, 56.20; H, 6.33; N, 19.08. MS: m/z (FAB) 384 (MNa⁺).

ACKNOWLEDGMENT

Al-Soud thanks Professor U. Beifuß of Fakultät für Chemie, Universität Hohenheim, Germany, for the laboratory facilities and hospitality.

REFERENCES

- [1] Mitsuya, H.; Yarchoan, R.; Broder, S. *Science* 1990, 249, 1553–1544.
- [2] De Clercq, E. *Med Res Rev* 1992, 13, 229–258.
- [3] Krayevsky, A. A. *Mole Biol (Russian)* 1992, 26, 725–744.
- [4] Okabe, M.; Sun, R.-C.; Tam, S. Y.-K.; Todaro, L. J.; Coffen, D. L. *J Org Chem* 1988, 53, 4780–4789.
- [5] Fleet, G. W.; Son, J. C.; Derome, A. E. *Tetrahedron* 1988, 44, 625–636.
- [6] Review: Walsh, C. *Tetrahedron* 1982, 38, 871–909.
- [7] Sandstrom, E.; Oberg, B. *Drug* 1993, 45, 488–508, 725–744.
- [8] Wigerinck, P.; Van Aerschot, A.; Janssen, G.; Claes, P.; Balzarini, J.; De Clercq, E.; Herdewijn, P. *J Med Chem* 1990, 33, 868–873.
- [9] Habich, D. *Synthesis* 1992, 358–360.
- [10] Ostrovskii, V. A.; Studentsov, E. P.; Poplavskii, V. S.; Ivanova, N. V.; Gurskaya, G. V.; Zavodnik, V. E.; Jasko, M. V.; Semizarov, D. G.; Krayevsky, A. A. *Nucleosides Nucleotides* 1995, 14, 1289–1300.
- [11] Petersen, G. V.; Platz, J.; Nielsen, C.; Wengel, J. *Synthesis* 1994, 823–826.
- [12] Lazrek, H. B.; Taourirte, M.; Oulih, T.; Kabbaj, Y.; Barascut, J. L.; Imbach, J. L.; Al-Masoudi, N.; Pfeleiderer, W. *Nucleosides Nucleotides* 1997, 16, 1073–1077.
- [13] Wigerinck, P.; Van Aerschot, A.; Claes, P.; Balzarini, J.; De Clercq, E.; Herdewijn, P. *J Heterocyclic Chem* 1989, 26, 1635–1642.
- [14] Hirota, K.; Hosono, H.; Kitade, Y.; Maki, Y.; Chu, C. K.; Schinazi, R. F.; Nakane, H.; Ono, K. *Chem Pharm Bull* 1990, 38, 2597–2601.
- [15] Al-Masoudi, N.; Hassan, N. A.; Al-Soud, Y. A.; Schmidt, P.; Gaafar, A. E.-D. M.; Weng, M.; Marino, S.; Schoch, A.; Amer, A.; Jochims, J. C. *J Chem Soc, Perkin Trans 1* 1998, 947–953, and references therein cited.
- [16] Al-Soud, Y. A.; Al-Masoudi, W. A.; El-Halawa, R. A.; Al-Masoudi, N. A. *Nucleosides Nucleotides* 1999, 18, 1985–1994.
- [17] Al-Masoudi, N. A.; Al-Soud, Y. A.; Geyer, A. *Tetrahedron* 1998, 55, 751–758.
- [18] Al-Masoudi, N. A.; Al-Soud, Y. A.; Lagoja, I. M. *Carbohydr Res* 1999, 318, 67–74.
- [19] Al-Soud, Y. A.; Al-Masoudi, N. A. *Arch Pharm Pharm Med Chem* 1999, 332, 143–144.
- [20] Al-Soud, Y. A.; Al-Masoudi, N. A. *Pharmazie* 2001, 56, 372–375.
- [21] Al-Soud, Y. A.; Halah, R. F.; Al-Masoudi, N. A. *Org Prep Proced Int (OPPI)* 2002, 34, 648–654.
- [22] Al-Soud, Y. A.; Al-Masoudi, N. A.; Ferwanah, A.-R. S. *Bioorg Med Chem (in press)*.
- [23] Monila, P.; Alajarin, M.; Arques, A. *Synthesis* 1982, 596–597.
- [24] Zehl, A.; Cech, D. *Liebigs Ann Chem* 1997, 595–600.
- [25] Al-Soud, Y. A.; Wirschun, W.; Hassan, N. A.; Maier, G.-M.; Jochims, J. C. *Synthesis* 1998, 721–728, and references therein cited.
- [26] Moon, M. W. *J Org Chem* 1972, 37, 383–385, 386–390, 2005–2009.
- [27] Moon, M. W.; Friedman, A. R.; Steinhardt, A. J. *Agric Food Chem* 1972, 20, 1187–1190.
- [28] El-Gazzar, A.-R. B. A.; Scholten, K.; Guo, Y.; Weißenbach, K.; Hitzler, M. G.; Roth, G.; Fischer, H.; Jochims, J. C. *J Chem Soc Perkin Trans 1* 1999, 1999–2010.
- [29] Butler, R. N.; Grogan, D. C.; McDonald, P. D.; Burke, L. A. *J Chem Soc, Perkin Trans 1* 1997, 3587–3590.
- [30] Wang, Q.; Jochims, J. C.; Köhlbrandt, St.; Dahlenburg, L.; Al-Talib, M.; Hamed, A.; Ismail, A. E. *Synthesis* 1992, 710–718.
- [31] Wang, Q.; Amer, A.; Mohr, S.; Ertel, E.; Jochims, J. C. *Tetrahedron* 1993, 49, 9973–9986, and references therein cited.
- [32] Müller, L. *J Am Chem Soc* 1979, 101, 4481–4484.
- [33] L'abbé, G.; Verhelst, G.; Toppet, S. *J Org Chem* 1976, 41, 3403–3406.
- [34] Wang, Q.; Al-Talib, M.; Jochims, J. C. *Chem Ber* 1994, 127, 541–547.
- [35] Willker, W.; Leibfritz, D.; Kerssebaum, R.; Bermel, W. *Mag Res Chem* 1993, 31, 287–292.